Zymeworks Inc. ZYME

Zymeworks Inc. es una empresa global de biotecnología. La empresa se dedica a la investigación, desarrollo y comercialización de biofármacos multifuncionales para tratar el cáncer y otras enfermedades graves. Su candidato a producto principal, zanidatamab, es un anticuerpo biespecífico que apunta a dos dominios distintos del receptor del factor de crecimiento epidérmico humano 2 (HER2). Su segundo candidato a producto, zanidatamab zovodotin, combina el diseño de anticuerpos biparatópicos de zanidatamab con su tecnología de conjugado de fármaco de anticuerpo ZymeLink auristatina (ADC), compuesta por su citotoxina (compuesto que mata células cancerosas) y un enlace cleavable. También está avanzando en una cartera de candidatos a productos preclínicos y programas en etapa de descubrimiento en oncología (incluidos agentes de inmunooncología) y otras áreas terapéuticas con énfasis en el desarrollo de candidatos a terapias de anticuerpos multi-específicos (MSAT) y ADC. Su cartera de candidatos a productos preclínicos incluye dos programas principales, ZW191 y ZW17.

• GlobeNewswire Inc. 28 sept

  Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

  Zymeworks completed its acquisition of Theravance Biopharma, adding YUPELRI to its portfolio and providing durable cash flows. The company updated 2026 guidance to $278-292 million in total revenue and $114-128 million in Adjusted EBITDA. The acquisition is expected to deliver mid-teens IRR with immediate accretive revenue and cash flow, financed through a $350 million non-recourse note from OMERS and $217.5 million in existing cash.

  

• Zacks Investment Research 1 sept

  JAZZ Rises on Updated OS Results From Gastric Cancer Study

  Jazz Pharmaceuticals announced second interim results from the HERIZON-GEA-01 study showing statistically significant overall survival improvements for Ziihera plus chemotherapy versus standard of care trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The three-drug regimen of Ziihera plus Tevimbra and chemotherapy also demonstrated improved OS hazard ratios with longer follow-up. These results support the recent FDA label expansion of Ziihera for first-line treatment in this indication, significantly expanding its commercial opportunity.

  

• GlobeNewswire Inc. 16 jul

  Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

  Zymeworks Inc. announced it will report second quarter 2026 financial results on August 6, 2026, but will not host an earnings conference call due to its pending acquisition of Theravance Biopharma. The company plans to provide updates on the combined business following the expected closing of the acquisition.

  

• GlobeNewswire Inc. 29 jun

  Zymeworks to Acquire Theravance Biopharma, Inc.

  Zymeworks announced a definitive agreement to acquire Theravance Biopharma for $17 per share ($929 million) to gain YUPELRI®, a nebulized LAMA for COPD treatment. The acquisition is financed through a $350 million non-recourse note from OMERS Life Sciences and Zymeworks' cash, with the deal expected to be accretive to earnings and cash flow. YUPELRI® generated $266.6 million in U.S. net sales in 2025 with 12% growth, positioning Zymeworks to diversify its revenue streams and fund R&D initiatives.

  

• GlobeNewswire Inc. 14 jun

  Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

  Zymeworks presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, showing a confirmed objective response rate of 78.6% in FRα-positive platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients. The drug demonstrated a favorable tolerability profile with median progression-free survival of 7.6 months across ovarian and endometrial cancer cohorts. Patient recruitment in dose optimization cohorts has been completed, supporting continued clinical development.